SUSAN OGDEN: Open Payments
NPI 1316317688 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,529 in 141 payments from 26 companies in 2025. Trend: 2023 $2,074 · 2024 $2,179 · 2025 $2,529
Food & beverage: $2,469Education: $60
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $349 |
| Bayer Healthcare Pharmaceuticals Inc. | 17 | $307 |
| Otsuka America Pharmaceutical, Inc. | 19 | $237 |
| ABBVIE INC. | 15 | $223 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $192 |
| Lilly USA, LLC | 12 | $179 |
| Amgen Inc. | 10 | $147 |
| Abbott Laboratories | 7 | $134 |
| Astellas Pharma US Inc | 5 | $119 |
| PFIZER INC. | 6 | $107 |
Products named: REXULTI, Kerendia, FARXIGA, CAPLYTA, UBRELVY, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA.
Industry payments across OK — which companies pay providers there.
